PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena

Zealand University Hospital

Status and phase: Unknown; Phase 4

Conditions: Healthy

Treatments: Drug: esomeprazole

Study type: Interventional

Funder types: Other

Identifiers

NCT00526006

2006-00673-145

Details and patient eligibility

About

The acid secretion in the stomach seems to increase after withdrawal of min. 8 wks of treatment with a PPI (protonpump inhibitor) It is unknown if this acid rebound phenomenon is of clinical significance. In a doubleblinded and placebocontrolled study healthy volunteers are randomized to treatment with placebo or PPI + placebo. Gastrointestinal symptoms are scored once a week and.

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18 years +

Exclusion criteria

• Dyspepsia, heartburn og acid regurgitation within the preceeding 4 weeks
• Previous treatment with PPI og H2RA
• Previous contact to doctor or hospital because of dyspepsia or reflux
• Pregnancy or breast feeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind